Free Trial

Merus Q4 2024 Earnings Report

Merus logo
$44.61 -0.22 (-0.49%)
As of 03/28/2025 04:00 PM Eastern

Merus EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.89
Beat/Miss
Beat by +$0.48
One Year Ago EPS
N/A

Merus Revenue Results

Actual Revenue
$9.14 million
Expected Revenue
$10.57 million
Beat/Miss
Missed by -$1.43 million
YoY Revenue Growth
N/A

Merus Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Merus Earnings Headlines

Merus' (MRUS) Buy Rating Reaffirmed at Guggenheim
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Merus (MRUS) Gets a Buy from Citi
Bank of America Securities Remains a Buy on Merus (MRUS)
See More Merus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merus and other key companies, straight to your email.

About Merus

Merus (NASDAQ:MRUS) N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

View Merus Profile

More Earnings Resources from MarketBeat